RETO shares declined roughly 73.6% over the last 30 days, falling from $12.40 to approximately $3.27, extending a steep multi-month selloff. The decline has unfolded alongside a series of reverse stock splits the company has used to maintain its Nasdaq Capital Market listing.

J-Star Holding (YMAT) shares declined roughly 21.5% over the last 30 days, falling from about $1.44 at the October 2 close to around $1.13 in recent trading. The pullback followed a series of sharp, high-volume spikes in September and October that proved difficult to sustain in a thinly traded, low-float micro-cap.

The $2 objective is a technical and psychological milestone drawn from public discussion, not an analyst consensus — AMBO currently has no credible, current sell-side price targets. With shares near $1.35, reaching $2 would require roughly 48% upside, a substantial move for a thinly traded micro-cap.

Radiopharm Theranostics (RADX) shares fell roughly 37% over the trailing 30 days, sliding from about $1.42 to below the $1.00 mark. The decline has been driven primarily by funding and dilution concerns rather than clinical setbacks, as the company moves through a multi-step capital-raising program.

The $1.30 target is drawn from public technical discussion, not an analyst consensus, because Abits Group Inc. (ABTS) has no credible, current analyst price targets. With shares trading near $1.05, reaching $1.30 would require roughly a 24% advance — a substantial move for a micro-cap bitcoin miner.

VCIG shares have fallen roughly 81% over the past 30 days, retreating from about $24.66 in early October to around $4.71 in early November. The decline extends a much deeper slide, with the stock down approximately 94% over the trailing three months from levels near $84 in early August.

The $1.50 central target is a fallback reference level, not an analyst price target — it reflects the company's most recent financing price of $1.55 per unit from a best-efforts offering. With shares near $1.00, reaching $1.50 would require a roughly 50% advance, a substantial move for a distressed micro-cap.

Ambow Education Holding Ltd. (AMBO) shares fell roughly 26% over the trailing 30 days, sliding from about $1.83 to $1.35 per share. The stock has also declined approximately one-third over the last quarter, extending a longer downtrend for the micro-cap education technology company.

SAIQ shares climbed roughly 163.8% over the last 30 days, rising from a closing price of $1.85 on October 2, 2026, to $4.88 on November 2, 2026. The advance reflects extreme post-listing volatility in a newly public, micro-cap space technology company rather than a single fundamental catalyst.

The central target discussed is $5.00 , roughly 33% above the most recent verified closing price of $3.75. Because credible analyst price targets are not yet available, this target comes from public market structure — notably the stock's 52-week high of $5.95 and the round-number $5 level — not from an analyst consensus.

The central target of $165 is the arithmetic mean of 12 recently updated, individually attributed analyst price targets, rounded from approximately $164.50. At a latest verified price near $146.52 , reaching $165 implies an upside of about 12.6% — a modest move rather than a large one.

Cenntro (CENN) shares fell roughly 91% over the trailing 30 days, sliding from about $3.78 to about $0.35 as dilution concerns intensified. The selloff accelerated after majority holders approved raising the authorized share count from 3 billion to 10 billion, a move widely read as paving the way for substantial future equity issuance.

Abits Group (ABTS) shares fell roughly 68.5% over the last 30 days, sliding from a closing price near $1.18 to approximately $0.37 at the latest quote. The decline was concentrated in a single session, when the stock dropped more than 60% intraday after weeks of comparatively narrow trading.

reAlpha Tech Corp. (AIRE) has fallen roughly 71% over the last 30 days, sliding from about $1.32 in early October to under $0.40. A $1.75 million public offering of 4,375,000 shares priced at $0.40 each, announced November 3, triggered a sharp single-session decline of more than 40%.

GMEX Robotics shares plunged -34.17% during regular trading, falling from a prior close of $0.8769 to $0.5773. The selloff followed the company's Nov 2 announcement of a deeply dilutive preferred-share conversion at just 23% of market price, alongside fiscal-2026 results showing a net loss widened to $17.37M from $0.68M.

The central target examined here is $10.00 , which is not a multi-analyst consensus but the only visible analyst price target reported by major data providers such as Barron's, Yahoo Finance, and Investing.com. Because coverage is limited to a single reported estimate, the $10 figure should be treated as a lone analyst objective rather than a true analyst consensus.

WF International (WXM) shares have fallen roughly 48.7% over the last 30 days, sliding from about $3.76 to $1.93 as selling pressure intensified. The decline extends a longer slide: the stock is down approximately 40% over the past quarter and is trading near its 52-week low.

J-Star Holding (YMAT) shares fell roughly 21% over the past 30 days, declining from around $1.44 to near $1.14 amid elevated volatility. The move reflects a sharp pullback from short-lived price spikes in October, when shares traded as high as the mid-$4 range intraday on October 12 before retreating.

IMTE shares have declined roughly 24% over the last 30 days, falling from around $0.49 to approximately $0.37, amid thin trading and elevated volatility. The pullback extends a broader multi-month downtrend, with the stock down about 20% over the last quarter.

IFRX dropped -11.86% during regular trading, sliding from a $1.77 prior close to $1.56 intraday. The decline followed InflaRx's Capital Markets Day, where it outlined an izicopan plan for ANCA-associated vasculitis with Phase 2 trials starting in 2027 and first efficacy data not expected until 2028 — a slower timeline that disappointed investors, alongside Q3 results showing no product revenue.